or human thrombin (n=153) applied topically to the target bleeding site with a gelatin sponge. Sixteen out of 126 (12.7%) patients in the Thrombin-JMI arm demonstrated seroconversion for at least ...

Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...